Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: TransThera Sciences (Nanjing), Inc.
Condition: Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
NCT04919642
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Completed No Results Found Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.